Novartis
网页2024年8月8日 · Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Information for patients and their …
Novartis United States of America
网页Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. At Novartis, we reimagine medicine in the broadest possible sense, from finding innovative treatments that improve and extend people’s lives, to making our healthcare system more accessible and equitable for all. …
About - Novartis
网页About. Learn more about Novartis and explore our core therapeutic areas and technology platforms. Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.
Novartis India
网页Novartis in Society integrated Report 2023. This report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse stakeholders. It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards.
Products - Novartis
网页Products | Novartis. Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Information for patients and their ...
Careers - Novartis
网页Careers at Novartis. Let’s reimagine medicine together. Function. Audit & Finance. BD&L & Strategic Planning. Commercial & General Management. Communications & Public Affairs. Data Science. Facilities & Administration.
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to ...
网页2021年12月22日 · Ad hoc announcement pursuant to Art. 53 LR. With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction 1; Leqvio provides effective and sustained LDL-C reduction of up to 52% vs. placebo for certain people with atherosclerotic …
网页11 DESCRIPTION. ENTRESTO (sacubitril and valsartan) is a combination of a neprilysin inhibitor and an angiotensin II receptor blocker. ENTRESTO contains a complex comprised of anionic forms of sacubitril and valsartan, sodium cations, and water molecules in the molar ratio of 1:1:3:2.5, respectively.
Novartis Pluvicto™ approved by FDA as first targeted radioligand ...
网页2022年3月23日 · Ad hoc announcement pursuant to Art. 53 LR . FDA also approved complementary diagnostic imaging agent, Locametz ®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions 2; Metastatic prostate cancer has a 5-year survival rate of less than 30% 3; mCRPC patients who progress on multiple lines of …
Patient assistance | Novartis United States of America
网页Co-Pay Assistance. If you are a patient with commercial insurance and are finding it difficult to afford your medicines, the Novartis co-pay assistance program may be able to help. Eligible patients pay no more than USD 30 for a 30-day prescription (USD 1 per day) through retail or mail order for the vast majority of our branded products ...